• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Scholar Rock Holding Corporation

    6/5/25 4:57:15 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001358219
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Scholar Rock Holding Corp.
    SEC File Number
    001-38501
    Address of Issuer
    301 Binney Street, 3rd Floor
    Cambridge
    MASSACHUSETTS
    02142
    Phone
    857-259-3860
    Name of Person for Whose Account the Securities are To Be Sold
    Edward Myles
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    J.P. Morgan Securities LLC
    390 Madison Avenue
    6th Floor
    New York � NY � 10017
    195996369679467676306/05/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/05/2025Stock Option ExerciseIssuerCheckbox not checked1959906/05/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Edward H. Myles
    C/o Issuer
    301 Binney Street, 3rd Floor
    Cambridge � MA � 02142
    Common03/10/20251422925005107

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/05/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Edward Myles

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SRRK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    4/3/2023$26.00Overweight
    Piper Sandler
    9/19/2022$30.00Buy
    H.C. Wainwright
    7/12/2022$20.00Buy
    Truist
    3/23/2022$24.00Buy
    H.C. Wainwright
    More analyst ratings

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, Florida. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's websit

      6/5/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

      Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the globa

      6/2/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock to Present at the Jefferies Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4 at 3:45 p.m. ET in New York City. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's website for app

      5/28/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    SEC Filings

    See more
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      6/5/25 4:57:15 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/3/25 4:02:04 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      5/29/25 4:51:49 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:46:02 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:44:33 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/16/23 5:46:56 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 9:00:58 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 7:24:55 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 1:22:38 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Financials

    Live finance-specific insights

    See more
    • Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, Florida. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's websit

      6/5/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

      Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the globa

      6/2/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock to Present at the Jefferies Global Healthcare Conference

      Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4 at 3:45 p.m. ET in New York City. A live webcast of the events may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. Archived replays of the webcasts will be available on the Company's website for app

      5/28/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Flier Jeffrey S. sold $180,584 worth of shares (6,075 units at $29.73), decreasing direct ownership by 20% to 24,070 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:32:03 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Burow Kristina sold $160,511 worth of shares (5,400 units at $29.72), decreasing direct ownership by 20% to 21,071 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:31:54 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gilman Michael sold $100,304 worth of shares (3,375 units at $29.72), decreasing direct ownership by 6% to 55,216 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      5/30/25 4:31:44 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

      - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

      8/16/21 4:05:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00 from $40.00 previously

      11/26/24 8:04:27 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously

      10/7/24 9:45:10 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Scholar Rock with a new price target

      Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00

      3/28/24 7:48:04 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care